Baxter International Inc (NYSE:BAX) SVP Jacqueline Kunzler Sells 593 Shares

Baxter International Inc (NYSE:BAX) SVP Jacqueline Kunzler sold 593 shares of Baxter International stock in a transaction that occurred on Wednesday, June 19th. The stock was sold at an average price of $80.46, for a total transaction of $47,712.78. Following the transaction, the senior vice president now owns 9,023 shares in the company, valued at $725,990.58. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of BAX stock traded down $0.88 on Friday, hitting $81.65. The company’s stock had a trading volume of 1,147,507 shares, compared to its average volume of 2,146,971. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.83 and a quick ratio of 1.30. Baxter International Inc has a fifty-two week low of $61.05 and a fifty-two week high of $82.85. The firm’s fifty day moving average price is $78.99. The firm has a market cap of $42.10 billion, a PE ratio of 26.77, a price-to-earnings-growth ratio of 1.94 and a beta of 0.99.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Thursday, April 25th. The medical instruments supplier reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.08. Baxter International had a net margin of 14.27% and a return on equity of 20.04%. The business had revenue of $2.63 billion during the quarter, compared to analyst estimates of $2.61 billion. During the same quarter in the previous year, the business earned $0.70 EPS. Baxter International’s quarterly revenue was down 1.7% compared to the same quarter last year. As a group, equities analysts predict that Baxter International Inc will post 3.32 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Monday, July 1st. Shareholders of record on Friday, June 7th were given a dividend of $0.22 per share. This is a positive change from Baxter International’s previous quarterly dividend of $0.19. The ex-dividend date was Thursday, June 6th. This represents a $0.88 dividend on an annualized basis and a yield of 1.08%. Baxter International’s payout ratio is currently 28.85%.

Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc raised its stake in shares of Baxter International by 1.3% in the third quarter. Vanguard Group Inc now owns 36,398,931 shares of the medical instruments supplier’s stock worth $2,805,993,000 after purchasing an additional 470,198 shares during the last quarter. Advisors Asset Management Inc. raised its stake in shares of Baxter International by 26.1% in the fourth quarter. Advisors Asset Management Inc. now owns 29,060 shares of the medical instruments supplier’s stock worth $1,913,000 after purchasing an additional 6,022 shares during the last quarter. WINTON GROUP Ltd raised its stake in shares of Baxter International by 219.8% in the fourth quarter. WINTON GROUP Ltd now owns 8,481 shares of the medical instruments supplier’s stock worth $558,000 after purchasing an additional 5,829 shares during the last quarter. Whittier Trust Co. raised its stake in shares of Baxter International by 5.7% in the fourth quarter. Whittier Trust Co. now owns 6,251 shares of the medical instruments supplier’s stock worth $411,000 after purchasing an additional 339 shares during the last quarter. Finally, Sullivan Bruyette Speros & Blaney LLC raised its stake in shares of Baxter International by 3.6% in the fourth quarter. Sullivan Bruyette Speros & Blaney LLC now owns 4,322 shares of the medical instruments supplier’s stock worth $284,000 after purchasing an additional 150 shares during the last quarter. 83.97% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts have recently commented on BAX shares. Cowen set a $75.00 price target on shares of Baxter International and gave the company a “hold” rating in a report on Monday, April 22nd. KeyCorp started coverage on shares of Baxter International in a report on Tuesday, June 25th. They set a “sector weight” rating on the stock. Wells Fargo & Co upgraded shares of Centurylink from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $12.00 to $14.00 in a report on Wednesday, June 26th. Zacks Investment Research cut shares of Gold Resource from a “hold” rating to a “sell” rating in a report on Friday, June 21st. Finally, Barclays boosted their price target on shares of Zimmer Biomet from $113.00 to $117.00 and gave the company an “underweight” rating in a report on Monday, April 15th. Four research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $79.20.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Further Reading: What is a Market Correction?

Insider Buying and Selling by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.